Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Enrique Báez-De la Fuente"'
Autor:
Martha I. Dávila-Rodríguez, Elva I. Cortés-Gutiérrez, Roberto Hernández-Valdés, Karla Guzmán-Cortés, Rosa E. De León-Cantú, Ricardo M. Cerda-Flores, Enrique Báez-De la Fuente
Publikováno v:
European Journal of Histochemistry, Vol 61, Iss 4 (2017)
The purpose of this study was to evaluate DNA damage in the whole genome of peripheral blood leukocytes from patients with acute myeloid leukemia (AML) compared with a control group using DNA breakage detection-fluorescent in situ hybridization (DBD-
Externí odkaz:
https://doaj.org/article/5586aa27d7e34f0c88764ecdae8b4947
Autor:
Gianmatteo Pica, Enrique Báez de la Fuente, Jan Van Droogenbroeck, Sorin Visanica, Brian Leber, Timothy Devos, Hacene Zerazhi, Antonio Almeida, Albert Kandra, Linda Chrit, Jean-Jacques Kiladjian, Dana Ranta, Juliane Morando, Lynda Foltz
Publikováno v:
Leukemia & Lymphoma. 60:3493-3502
Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Expanded Treatment Protocol study (NCT02292446) of ruxolitinib
Autor:
Elva I. Cortés-Gutiérrez, Ricardo M. Cerda-Flores, Enrique Báez de la Fuente, Roberto Hernandez-Valdes, Karla Guzmán-Cortés, Rosa E De León-Cantú, Martha I. Dávila-Rodríguez
Publikováno v:
European Journal of Histochemistry, Vol 61, Iss 4 (2017)
European Journal of Histochemistry : EJH
European Journal of Histochemistry : EJH
The purpose of this study was to evaluate DNA damage in the whole genome of peripheral blood leukocytes from patients with acute myeloid leukemia (AML) compared with a control group using DNA breakage detection-fluorescent in situ hybridization (DBD-
Autor:
Mauricio Reyes Cartes, Sorin Visanica, Gianmatteo Pica, Antonio Almeida, Timothy Devos, Jean-Jacques Kiladjian, Hacene Zerazhi, Enrique Báez de la Fuente, Juliane Morando, Lynda Foltz, Zhaoyu Yin, Jan Van Droogenbroeck, Brian Leber, Linda Chrit, Dana Ranta
Publikováno v:
Blood. 132:1774-1774
BACKGROUND Few Tx options are available for pts with inadequately controlled PV. European LeukemiaNet defined resistance/intolerance was seen in ≈25% pts treated with HU (Alvarez-Larran et al, 2012). In the HU-resistant/intolerant PV pts evaluated
Publikováno v:
Revista medica del Instituto Mexicano del Seguro Social. 52(3)
Resistance and intolerance to imatinib in patients with chronic myeloid leukemia requires alternative therapies. Nilotinib provides a choice as a second-line treatment. The objective of this report was to show the results of a group of patients with
Publikováno v:
Revista medica del Instituto Mexicano del Seguro Social. 52(3)
Imatinib has changed the natural history of chronic myeloid leukemia. There are women with chronic myeloid leukemia in reproductive age with pregnancy desires. The aim of this case was to report the course and outcome of pregnancy in a patient with c
Autor:
Martha I, Dávila-Rodríguez, Ricardo M, Cerda-Flores, Carlos H, Leal-Garza, Rosa M, Arana-Trejo, Enrique, Báez-de la Fuente, Elva I, Cortés-Gutiérrez
Publikováno v:
Gaceta medica de Mexico. 140(6)
Our aim was to characterize the cytogenetic profile that displays a certain phase of chronic myelogenous leukemia (CML), offering new directions for investigation of the etiology to the molecular level. In Mexico, data does not exist in this regard;